1-[2(S)-hydroxy-3(S)-amino-4-phenyl-butyl]-1-[cyclohexylmethyl]-2-[tert-butoxycarbonyl]-hydrazine | 161852-66-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-[2(S)-hydroxy-3(S)-amino-4-phenyl-butyl]-1-[cyclohexylmethyl]-2-[tert-butoxycarbonyl]-hydrazine
• 英文别名: tert-butyl N-[[(2S,3S)-3-amino-2-hydroxy-4-phenylbutyl]-(cyclohexylmethyl)amino]carbamate
• CAS: 161852-66-0
• 化学式: C₂₂H₃₇N₃O₃
• 分子量: 391.554
• InChiKey: YOWPQPKSDMASQF-PMACEKPBSA-N

物化性质

• 密度：
  1.092±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  28
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.68
• 拓扑面积：
  87.8
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-[2(S)-hydroxy-3(S)-amino-4-phenyl-butyl]-1-[cyclohexylmethyl]-2-[tert-butoxycarbonyl]-hydrazine 在 N-甲基吗啉 、 甲酸 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 3-羟基-1,2,3-苯并三嗪-4(3H)-酮 、 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 反应 82.0h， 生成 (2S)-N-[(2S,3S)-4-[[[(2S)-2-amino-3-methylbutanoyl]amino]-(cyclohexylmethyl)amino]-3-hydroxy-1-phenylbutan-2-yl]-2-(quinoline-2-carbonylamino)butanediamide
  参考文献：
  名称：

  Aza-Peptide Analogs as Potent Human Immunodeficiency Virus Type-1 Protease Inhibitors with Oral Bioavailability

  摘要：

  A series of aza-peptide analogs with a (hydroxyethyl)hydrazine isostere has been synthesized as HIV-1 protease inhibitors using a simple synthetic scheme. Structure-activity studies based on the X-ray of a previously described inhibitor-enzyme complex led to potent inhibitors with antiviral activity in the low-nanomolar range. The S-configuration of the transition-state hydroxyl group was preferred in this series. Small modifications of the P2P3 and P-2'P-3' substituents had little effect on enzyme inhibition but greatly influenced the pharmacokinetic profile. As a result of these studies, the symmetrically acylated compound 8a and its close analog 24a bearing a methyl carbamate in P-3 and an ethyl carbamate in P-3' position were identified as potent inhibitors with plasma concentrations exceeding antiviral ED(50) values 150-fold following oral application in mice.

  DOI：

  10.1021/jm960022p
• 作为产物：
  描述：

  N-1-(tert-butoxycarbonyl)-N-2-(cyclohexylmethyl)hydrazine 在 potassium carbonate 作用下， 以 甲醇 为溶剂， 反应 32.0h， 生成 1-[2(S)-hydroxy-3(S)-amino-4-phenyl-butyl]-1-[cyclohexylmethyl]-2-[tert-butoxycarbonyl]-hydrazine
  参考文献：
  名称：

  Aza-Peptide Analogs as Potent Human Immunodeficiency Virus Type-1 Protease Inhibitors with Oral Bioavailability

  摘要：

  A series of aza-peptide analogs with a (hydroxyethyl)hydrazine isostere has been synthesized as HIV-1 protease inhibitors using a simple synthetic scheme. Structure-activity studies based on the X-ray of a previously described inhibitor-enzyme complex led to potent inhibitors with antiviral activity in the low-nanomolar range. The S-configuration of the transition-state hydroxyl group was preferred in this series. Small modifications of the P2P3 and P-2'P-3' substituents had little effect on enzyme inhibition but greatly influenced the pharmacokinetic profile. As a result of these studies, the symmetrically acylated compound 8a and its close analog 24a bearing a methyl carbamate in P-3 and an ethyl carbamate in P-3' position were identified as potent inhibitors with plasma concentrations exceeding antiviral ED(50) values 150-fold following oral application in mice.

  DOI：

  10.1021/jm960022p

文献信息

• Methods of treating alzheimer's disease
  申请人：Schostarez Heinrich

  公开号：US20050130941A1

  公开（公告）日：2005-06-16

  Disclosed are methods for treating Alzheimer's disease, and other diseases, and/or inhibiting beta-secretase enzyme, and/or inhibiting deposition of A beta peptide in a mammal, by use of hydrazine compounds of formula (I) wherein the variables R 1 -R 9 are defined herein.

  本发明涉及使用式(I)中变量R1-R9所定义的肼化合物治疗阿尔茨海默病和其他疾病，抑制β-分泌酶酶活性，抑制A beta肽在哺乳动物体内的沉积。
• Antiretroviral hydrazine derivatives
  申请人：Novartis Corporation

  公开号：US05753652A1

  公开（公告）日：1998-05-19

  The invention relates to compounds of formula ##STR1## and salts, pharmaceutical compositions, intermediates and processes of preparation thereof.

  本发明涉及式子##STR1##的化合物及其盐、药物组合物、中间体和制备方法。
• Antiretrovirale hydrazinderivate
  申请人：CIBA-GEIGY AG

  公开号：EP0604368A1

  公开（公告）日：1994-06-29

  Beschrieben werden Verbindungen der Formel worin R₁ und R₉ unabhängig voneinander Wasserstoff, Acyl, unsubstituiertes oder substituiertes Alkyl; Sulfo; oder durch unsubstituiertes oder substituiertes Alkyl, Aryl oder Heterocyclyl substituiertes Sulfonyl bedeuten, mit der Massgabe, dass höchstens einer der Reste R₁ und R₉ Wasserstoff bedeutet; und R₂ und R₈ jeweils unabhängig voneinander Wasserstoff oder unsubstituiertes oder substituiertes Alkyl bedeuten; R₃ und R₄ unabhängig voneinander Wasserstoff, unsubstituiertes oder substituiertes Alkyl, unsubstituiertes oder substituiertes Cycloalkyl oder Aryl bedeuten; R₅ Acyloxy bedeutet; R₆ Wasserstoff bedeutet; und R₇ unsubstituiertes oder substituiertes Alkyl, unsubstituiertes oder substituiertes Cycloalkyl oder Aryl bedeutet; sowie Salze der genannten Verbindungen, sofern salzbildende Gruppen vorliegen; diese Verbindungen zeigen antiretrovirale Wirksamkeit.

  式中的化合物 其中 R₁ 和 R𠢙 相互独立地为氢、酰基、未取代或取代的烷基；磺酰基；或被未取代或取代的烷基、芳基或杂环基取代的磺酰基，但 R₁ 和 R𠢙 自由基中最多有一个是氢；R₂ 和 R₈ 相互独立地为氢或未取代或取代的烷基； R₃ 和 R₄ 各自独立地为氢、未取代或取代的烷基、未取代或取代的环烷基或芳基； R₅ 表示酰氧基； R₆ 表示氢； R₇ 表示未取代或取代的烷基、未取代或取代的环烷基或芳基； 以及上述化合物的盐类，只要存在成盐基团；这些化合物具有抗逆转录病毒活性。
• METHODS OF TREATING ALZHEIMER'S DISEASE
  申请人：Elan Pharmaceuticals, Inc.

  公开号：EP1392315A1

  公开（公告）日：2004-03-03
• US5753652A
  申请人：——

  公开号：US5753652A

  公开（公告）日：1998-05-19